Call Now

Human TRAIL R4 / CD264 / TNFRSF10D Protein (His Tag)

CD264,DCR2,TRAIL-R4,TRAILR4,TRUNDD

Catalog Number P10413-H08H
Organism Species Human
Host Human Cells
Synonyms CD264,DCR2,TRAIL-R4,TRAILR4,TRUNDD
Molecular Weight The recombinant human TNFRSF10D consists of 167 amino acids after removal of the signal peptide and has a predicted a molecular mass of 18.4 kDa. As a result of glycosylation, the apparent molecular mass of rhTNFRSF10D is approximately 30-40 kDa in SDS-PAGE under reducing conditions.
predicted N Ala 56
SDS-PAGE
Purity > 90 % as determined by SDS-PAGE
Protein Construction A DNA sequence encoding the human TNFRSF10D (NP_003831.2) extracellular domain (Met 1-His 211) was fused with a polyhistidine tag at the C-terminus.
Bio-activity 1. Measured by its binding ability in a functional ELISA. Immobilized human TNFRSF10D at 10 μg/ml (100 μl/well) can bind biotinylated TNFSF10 with a linear range of 0.625-40 ng/ml.
2. Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L‑929 mouse fibroblast cells treated with TRAIL. The ED50 for this effect is typically 0.05-0.5 μg/mL in the presence of 20 ng/ml Recombinant Human TRAIL/TNFSF10.
Research Area Cancer |Signal transduction |Growth Factor & Receptor |Tumor Necrosis Factor (TNF) & Receptor |TNF Receptor
Formulation Lyophilized from sterile PBS, pH 7.4
1. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Tumor necrosis factor receptor superfamily member 10D (TNFRSF10D), also known as TNF-related apoptosis-inducing ligand receptor 4 (TRAIL R4), CD264, and Decoy receptor 2, is a member of the TNF-receptor superfamily. This receptor contains an extracellular TRAIL-binding domain, a transmembrane domain, and a truncated cytoplamic death domain. This receptor does not induce apoptosis, and has been shown to play an inhibitory role in TRAIL-induced cell apoptosis. TRAIL R4/CD264/TNFRSF10D is widely expressed, in particular in fetal kidney, lung and liver, and in adult testis and liver. TRAIL R4/CD264/TNFRSF10D is also expressed in peripheral blood leukocytes, colon and small intestine, ovary, prostate, thymus, spleen, pancreas, kidney, lung, placenta and heart. The signaling capacity of TRAIL R4 is similar to that of TRAIL R1 and TRAIL R2 with respect to NF-κB activation, but differs in its inability to induce apoptosis. TRAIL R4 retains a C-terminal element containing one third of a consensus death domain motif. Transient overexpression of TRAIL R4 in cells normally sensitive to TRAIL-mediated killing confers complete protection, suggesting that one function of TRAIL R4 may be inhibition of TRAIL cytotoxicity.
Reference
  • Degli-Esposti MA, et al. (1997) The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 7(6): 813-20.
  • Meng RD, et al. (2000) The TRAIL decoy receptor TRUNDD (DcR2, TRAIL-R4) is induced by adenovirus-p53 overexpression and can delay TRAIL-, p53-, and KILLER/DR5-dependent colon cancer apoptosis. Mol Ther. 1(2): 130-44.
  • Bouralexis S, et al. (2003) Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy. Br J Cancer. 89(1): 206-14.